Published in J Mol Diagn on October 02, 2008
Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet (2009) 3.01
Accurate prediction of genetic values for complex traits by whole-genome resequencing. Genetics (2010) 2.79
High-resolution, high-throughput HLA genotyping by next-generation sequencing. Tissue Antigens (2009) 2.64
Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med (2014) 2.41
Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet (2014) 2.33
Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat (2010) 2.29
Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II. BMC Bioinformatics (2012) 1.59
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J (2010) 1.52
Comprehensive mutation analysis for congenital muscular dystrophy: a clinical PCR-based enrichment and next-generation sequencing panel. PLoS One (2013) 1.51
Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: implications for application to clinical testing. Genet Med (2011) 1.42
Next generation sequence analysis for mitochondrial disorders. Genome Med (2009) 1.42
Semi-automated library preparation for high-throughput DNA sequencing platforms. J Biomed Biotechnol (2010) 1.22
Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol (2014) 1.21
Next generation sequencing in research and diagnostics of ocular birth defects. Mol Genet Metab (2010) 1.21
Mapping the incidentalome: estimating incidental findings generated through clinical pharmacogenomics testing. Genet Med (2012) 1.17
Genetics specialists' perspectives on disclosure of genomic incidental findings in the clinical setting. Patient Educ Couns (2012) 1.17
Current genetic methodologies in the identification of disaster victims and in forensic analysis. J Appl Genet (2011) 1.07
Evaluation of second-generation sequencing of 19 dilated cardiomyopathy genes for clinical applications. J Mol Diagn (2010) 1.04
Discovery of genes related to insecticide resistance in Bactrocera dorsalis by functional genomic analysis of a de novo assembled transcriptome. PLoS One (2012) 1.02
Genometa--a fast and accurate classifier for short metagenomic shotgun reads. PLoS One (2012) 1.02
Empirical validation of viral quasispecies assembly algorithms: state-of-the-art and challenges. Sci Rep (2013) 1.01
Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome. Appl Clin Genet (2015) 1.00
Single-step capture and sequencing of natural DNA for detection of BRCA1 mutations. Genome Res (2011) 0.99
Review of massively parallel DNA sequencing technologies. Hugo J (2011) 0.96
Assessment of target enrichment platforms using massively parallel sequencing for the mutation detection for congenital muscular dystrophy. J Mol Diagn (2012) 0.94
Next-generation sequencing. Breast Cancer Res (2009) 0.94
Genetic pathways leading to therapy-related myeloid neoplasms. Mediterr J Hematol Infect Dis (2011) 0.93
Next-generation sequencing in genetic hearing loss. Genet Test Mol Biomarkers (2013) 0.93
Systems biology in the context of big data and networks. Biomed Res Int (2014) 0.90
CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR. J Med Genet (2010) 0.89
A closer look at the recommended criteria for disclosing genetic results: perspectives of medical genetic specialists, genomic researchers, and institutional review board chairs. J Genet Couns (2013) 0.88
Detection of novel mutations that cause autosomal dominant retinitis pigmentosa in candidate genes by long-range PCR amplification and next-generation sequencing. Mol Vis (2013) 0.88
Evidence for the importance of personalized molecular profiling in pancreatic cancer. Pancreas (2014) 0.83
A massive parallel sequencing workflow for diagnostic genetic testing of mismatch repair genes. Mol Genet Genomic Med (2014) 0.82
Targeted genome-wide enrichment of functional regions. PLoS One (2010) 0.81
Management of Incidental Findings in the Era of Next-generation Sequencing. Curr Genomics (2015) 0.81
Systematic pharmacogenomics analysis of a Malay whole genome: proof of concept for personalized medicine. PLoS One (2013) 0.81
Evaluation of autosomal dominant retinal dystrophy genes in an unaffected cohort suggests rare or private missense variants may often be benign. Mol Vis (2013) 0.80
Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing. Nucleic Acids Res (2016) 0.79
Targeted 'next-generation' sequencing in anophthalmia and microphthalmia patients confirms SOX2, OTX2 and FOXE3 mutations. BMC Med Genet (2011) 0.79
Managing Expectational Language: Translational genetic professionals consider the clinical potential of next-generation sequencing technologies. New Genet Soc (2014) 0.78
Privacy and data management in the era of massively parallel next-generation sequencing. Expert Rev Mol Diagn (2011) 0.78
Cracking the Code of Human Diseases Using Next-Generation Sequencing: Applications, Challenges, and Perspectives. Biomed Res Int (2015) 0.78
Improving mapping and SNP-calling performance in multiplexed targeted next-generation sequencing. BMC Genomics (2012) 0.78
Cost analysis of whole genome sequencing in German clinical practice. Eur J Health Econ (2016) 0.77
Standardization and quality management in next-generation sequencing. Appl Transl Genom (2016) 0.77
Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States. ISRN Oncol (2013) 0.77
Genomics pipelines and data integration: challenges and opportunities in the research setting. Expert Rev Mol Diagn (2017) 0.77
Single-variant and multi-variant trend tests for genetic association with next-generation sequencing that are robust to sequencing error. Hum Hered (2013) 0.76
SeqSharp: A general approach for improving cycle-sequencing that facilitates a robust one-step combined amplification and sequencing method. J Mol Diagn (2010) 0.76
The next generation of cancer management. Cancer Biol Med (2016) 0.75
New COL6A6 variant detected by whole-exome sequencing is linked to break points in intron 4 and 3'-UTR, deleting exon 5 of RHO, and causing adRP. Mol Vis (2015) 0.75
Transcriptional analysis of endocrine disruption using zebrafish and massively parallel sequencing. J Mol Endocrinol (2014) 0.75
Microbial Ecology: Where are we now? Postdoc J (2016) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
A new method for sequencing DNA. Proc Natl Acad Sci U S A (1977) 250.51
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
SOAP: short oligonucleotide alignment program. Bioinformatics (2008) 68.13
Serial analysis of gene expression. Science (1995) 60.15
NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res (2006) 48.10
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
The impact of next-generation sequencing technology on genetics. Trends Genet (2008) 21.07
Accurate multiplex polony sequencing of an evolved bacterial genome. Science (2005) 20.91
Genome-wide in situ exon capture for selective resequencing. Nat Genet (2007) 19.97
Direct selection of human genomic loci by microarray hybridization. Nat Methods (2007) 17.73
Multiplex amplification of large sets of human exons. Nat Methods (2007) 15.11
Pyrosequencing sheds light on DNA sequencing. Genome Res (2001) 11.87
Single-molecule DNA sequencing of a viral genome. Science (2008) 11.66
Microarray-based genomic selection for high-throughput resequencing. Nat Methods (2007) 9.62
Advanced sequencing technologies: methods and goals. Nat Rev Genet (2004) 9.31
The use of coded PCR primers enables high-throughput sequencing of multiple homolog amplification products by 454 parallel sequencing. PLoS One (2007) 9.17
ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med (2008) 9.13
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Zero-mode waveguides for single-molecule analysis at high concentrations. Science (2003) 7.69
The incidentalome: a threat to genomic medicine. JAMA (2006) 7.24
Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol (2003) 7.02
Gene sequencing. The race for the $1000 genome. Science (2006) 6.76
Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res (2005) 6.32
Padlock probes: circularizing oligonucleotides for localized DNA detection. Science (1994) 6.17
Sequence information can be obtained from single DNA molecules. Proc Natl Acad Sci U S A (2003) 5.24
A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet (2007) 5.17
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer (2007) 4.74
Multigene amplification and massively parallel sequencing for cancer mutation discovery. Proc Natl Acad Sci U S A (2007) 3.93
Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med (2001) 3.72
Multiplex amplification enabled by selective circularization of large sets of genomic DNA fragments. Nucleic Acids Res (2005) 3.59
Targeted high-throughput sequencing of tagged nucleic acid samples. Nucleic Acids Res (2007) 3.56
Sequencing breakthroughs for genomic ecology and evolutionary biology. Mol Ecol Resour (2008) 2.75
Multiplex amplification of all coding sequences within 10 cancer genes by Gene-Collector. Nucleic Acids Res (2007) 2.70
DeepSAGE--digital transcriptomics with high sensitivity, simple experimental protocol and multiplexing of samples. Nucleic Acids Res (2006) 2.66
Large-scale pyrosequencing of synthetic DNA: a comparison with results from Sanger dideoxy sequencing. Electrophoresis (2006) 2.63
High-throughput genotyping of single nucleotide polymorphisms with rolling circle amplification. BMC Genomics (2001) 2.25
DNA sequencing: bench to bedside and beyond. Nucleic Acids Res (2007) 2.25
Highly accurate classification of Watson-Crick basepairs on termini of single DNA molecules. Biophys J (2003) 2.02
Technical standards and guidelines: molecular genetic testing for ultra-rare disorders. Genet Med (2005) 2.00
Automation for genomics, part two: sequencers, microarrays, and future trends. Genome Res (2000) 1.96
International genome project launched. Nature (2008) 1.86
American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med (2001) 1.70
PieceMaker: selection of DNA fragments for selector-guided multiplex amplification. Nucleic Acids Res (2005) 1.46
MegaPlex PCR: a strategy for multiplex amplification. Nat Methods (2007) 1.27
Connector inversion probe technology: a powerful one-primer multiplex DNA amplification system for numerous scientific applications. PLoS One (2007) 1.18
Predictive genetic testing: from basic research to clinical practice. Science (1997) 1.15
Human genetics: Dr Watson's base pairs. Nature (2008) 1.11
Extensive sequencing of the CFTR gene: lessons learned from the first 157 patient samples. Hum Genet (2005) 1.05
Paired-end genomic signature tags: a method for the functional analysis of genomes and epigenomes. Genet Eng (N Y) (2007) 0.99
Are p.I148T, p.R74W and p.D1270N cystic fibrosis causing mutations? BMC Med Genet (2004) 0.99
Genetic testing and the clinical laboratory improvement amendments of 1988: present and future. Clin Chem (1999) 0.92
Ethical issues raised by genetic testing with oligonucleotide microarrays. Mol Biotechnol (2003) 0.88
Genomics sizes up. Nature (2008) 0.87
Arrayed identification of DNA signatures. Expert Rev Mol Diagn (2007) 0.86
New quality assurance standards for rare disease testing. Genet Med (2008) 0.83
Regulations for implementing the Clinical Laboratory Improvement Amendments of 1988: a summary. MMWR Recomm Rep (1992) 0.80
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med (2013) 22.73
ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med (2008) 9.13
DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med (2011) 4.98
Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet Med (2012) 4.04
Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med (2004) 3.32
DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med (2012) 3.18
Standards and guidelines for CFTR mutation testing. Genet Med (2002) 1.94
Mouse model for human arginase deficiency. Mol Cell Biol (2002) 1.88
College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med (2014) 1.84
Arginases I and II: do their functions overlap? Mol Genet Metab (2004) 1.67
Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. J Mol Diagn (2012) 1.57
Genetic testing as part of the early hearing detection and intervention (EHDI) process. Genet Med (2004) 1.48
Stuck between a scalpel and a rock, or molecular pathology and legal-ethical issues in use of tissues for clinical care and research: what must a pathologist know? Am J Clin Pathol (2012) 1.47
Developing a sustainable process to provide quality control materials for genetic testing. Genet Med (2005) 1.23
Estimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing. Genet Med (2003) 1.21
Widespread expression of arginase I in mouse tissues. Biochemical and physiological implications. J Histochem Cytochem (2003) 1.18
Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy. PLoS One (2010) 1.16
Cystic fibrosis carrier screening: issues in implementation. Genet Med (2003) 1.14
Monitoring standards for molecular genetic testing in the United Kingdom, the Netherlands, and Ireland. Genet Test (2006) 1.12
Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia. Mol Genet Metab (2007) 1.11
An electrochemical detection scheme for identification of single nucleotide polymorphisms using hairpin-forming probes. Nucleic Acids Res (2002) 1.10
Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector. Mol Ther (2009) 1.10
Ornithine deficiency in the arginase double knockout mouse. Mol Genet Metab (2006) 1.08
Testing and reporting ACMG cystic fibrosis mutation panel results. Genet Test (2007) 1.05
Contrasting features of urea cycle disorders in human patients and knockout mouse models. Mol Genet Metab (2007) 1.04
Alternative approaches to proficiency testing in molecular genetics. Clin Chem (2003) 1.02
Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy. Mol Ther (2012) 1.02
Expression of the liver form of arginase in erythrocytes. Mol Genet Metab (2002) 0.98
De Novo variants in the KMT2A (MLL) gene causing atypical Wiedemann-Steiner syndrome in two unrelated individuals identified by clinical exome sequencing. BMC Med Genet (2014) 0.98
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn (2012) 0.97
Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse. Mol Genet Metab (2013) 0.94
Current landscape and new paradigms of proficiency testing and external quality assessment for molecular genetics. Arch Pathol Lab Med (2013) 0.94
Deaf adults' reasons for genetic testing depend on cultural affiliation: results from a prospective, longitudinal genetic counseling and testing study. J Deaf Stud Deaf Educ (2010) 0.93
Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med (2009) 0.93
Diagnosis and management of familial Mediterranean fever: integrating medical genetics in a dedicated interdisciplinary clinic. Genet Med (2011) 0.92
Infant hearing loss and connexin testing in a diverse population. Genet Med (2008) 0.91
Expression of arginase II in prostate cancer. Int J Oncol (2008) 0.90
Cloning and characterization of human agmatinase. Mol Genet Metab (2002) 0.90
Ethnic differences in parental perceptions of genetic testing for deaf infants. J Genet Couns (2007) 0.89
Polyamine homeostasis in arginase knockout mice. Am J Physiol Cell Physiol (2007) 0.88
Colchicine's other indication--effect of FDA action. N Engl J Med (2010) 0.86
Prenatal screening for cystic fibrosis: past, present and future. Expert Rev Mol Diagn (2004) 0.86
The fate of newborn screening blood spots. Pediatr Res (2010) 0.85
A prospective, longitudinal study of the impact of GJB2/GJB6 genetic testing on the beliefs and attitudes of parents of deaf and hard-of-hearing infants. Am J Med Genet A (2009) 0.85
Microelectronic array system for molecular diagnostic genotyping: Nanogen NanoChip 400 and molecular biology workstation. Expert Rev Mol Diagn (2006) 0.84
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
Sharing GJB2/GJB6 genetic test information with family members. J Genet Couns (2007) 0.82
Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate (2008) 0.81
Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing. J Mol Diagn (2009) 0.81
The clinical significance of circulating tumor cells in the peripheral blood. Diagn Mol Pathol (2006) 0.81
Bayesian analysis for cystic fibrosis risks in prenatal and carrier screening. Genet Med (2004) 0.80
Variable penetrance and expressivity of the splice altering 5T sequence in the cystic fibrosis gene. Genet Test (2007) 0.80
A novel method for creating artificial mutant samples for performance evaluation and quality control in clinical molecular genetics. J Mol Diagn (2005) 0.78
Privacy and data management in the era of massively parallel next-generation sequencing. Expert Rev Mol Diagn (2011) 0.78
Discordant pursuit asymmetry and esotropia in monozygous twins. Am J Ophthalmol (2002) 0.78
Arginase expression in mouse embryonic development. Mech Dev (2002) 0.78
Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. J Hematop (2009) 0.78
Cystic fibrosis mutations in Costa Rica. Hum Biol (2003) 0.77
Cystic fibrosis mutation analysis: how many is enough? Genet Med (2004) 0.77
An exon 1 deletion in OTC identified using chromosomal microarray analysis in a mother and her two affected deceased newborns: implications for the prenatal diagnosis of ornithine transcarbamylase deficiency. Mol Genet Metab (2010) 0.75
Prelingual siblings of children with GJB2 hearing loss: issues to consider. Arch Otolaryngol Head Neck Surg (2005) 0.75
Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests. Genet Med (2005) 0.75
Ordering genetic tests and interpreting the results. Adv Otorhinolaryngol (2011) 0.75
Direct-to-consumer genotyping: are we ready for a brave new world? Clin Chem (2010) 0.75